Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.56 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.53 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.53 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.53 |
| ▸ | TERT | O14746 | 1/20 | 0.52 |
| ▸ | DTYMK | P23919 | 2/20 | 0.51 |
| ▸ | NT5E | P21589 | 1/20 | 0.48 |
| ▸ | STING1 | Q86WV6 | 7/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13359725 | 1.00 | POLB (0.61) | POLBENPP1P2RY1F2P2RY2 | |
| SCHEMBL13326140 | 0.99 | POLB (0.60) | POLBENPP1P2RY1F2P2RY2 | |
| SCHEMBL14389942 | 0.99 | POLB (0.60) | POLBENPP1P2RY1F2P2RY2 | |
| SCHEMBL22434625 | 0.94 | POLB (0.62) | POLBENPP1P2RY1F2P2RY2 | |
| SCHEMBL14389999 | 0.93 | F2 (0.54) | POLBENPP1P2RY1F2P2RY2 | |
| SCHEMBL13326121 | 0.93 | F2 (0.54) | POLBENPP1P2RY1F2P2RY2 | |
| SCHEMBL14389990 | 0.93 | F2 (0.54) | POLBENPP1P2RY1F2P2RY2 | |
| SCHEMBL14389939 | 0.93 | F2 (0.54) | POLBENPP1P2RY1F2P2RY2 | |
| SCHEMBL13326155 | 0.93 | F2 (0.54) | POLBENPP1P2RY1F2P2RY2 | |
| SCHEMBL13326124 | 0.93 | F2 (0.54) | POLBENPP1P2RY1F2P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270359-A1 | Nucleic Acid-Based Compounds and Methods of Use Thereof | IYER RADHAKRISHNAN P | 2007-11-22 | — | — | US | disclosed |
| US-7256179-B2 | Nucleic acid-based compounds and methods of use thereof | MIGENIX, INC. (CA) | 2007-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270359-A1 | Nucleic Acid-Based Compounds and Methods of Use Thereof | NT5C3B, HAVCR2, NSUN2 | POLB 8/4885ENPP1 344/4885P2RY1 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.